Results 131 to 140 of about 25,701,198 (388)

Circulating tumor DNA (ctDNA) trajectories predict survival in trifluridine/tipiracil‐treated metastatic colorectal cancer patients

open access: yesMolecular Oncology, EarlyView.
The authors applied joint/mixed models that predict mortality of trifluridine/tipiracil‐treated metastatic colorectal cancer patients based on circulating tumor DNA (ctDNA) trajectories. Patients at high risk of death could be spared aggressive therapy with the prospect of a higher quality of life in their remaining lifetime, whereas patients with a ...
Matthias Unseld   +7 more
wiley   +1 more source

Navigating Data Acquisition and Data Quality Validation of Large Databases: Practical Lessons

open access: yesInternational Journal of Population Data Science
Objective Have you ever been frustrated when working to acquire data? Have you experienced the trials and tribulations of readying data? ‘Best laid plans often go awry’.
Nedeene Hudema   +4 more
doaj   +1 more source

Integrative analysis of circulating tumor cells (CTCs) and exosomes from small‐cell lung cancer (SCLC) patients: a comprehensive approach

open access: yesMolecular Oncology, EarlyView.
This study simultaneously investigated circulating tumor cells (CTCs) and exosomes from small‐cell lung cancer (SCLC) patients. The elevated expression of JUNB and CXCR4 in CTCs was a poor prognostic factor for SCLC patients, whereas exosomal overexpression of these biomarkers revealed a high discrimination ability of patients from healthy individuals,
Dimitrios Papakonstantinou   +13 more
wiley   +1 more source

Improving the Quality of Quality Measurement [PDF]

open access: yesJournal of General Internal Medicine, 2016
David W. Baker, Cheryl L. Damberg
openaire   +2 more sources

Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR

open access: yesMolecular Oncology, EarlyView.
Analysis of ESR1 mutations in plasma cell‐free DNA (cfDNA) is highly important for the selection of treatment in patients with breast cancer. Using multiplex‐ddPCR and identical blood draws, we investigated whether circulating tumor cells (CTCs) and cfDNA provide similar or complementary information for ESR1 mutations.
Stavroula Smilkou   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy